Lowers the risk of stroke. ANDA 206392, held by Amneal Pharmaceuticals. Aspirin; Dipyridamole.
As of Nov 22, 2026, ANDA 206392 (Aspirin and Dipyridamole), held by Amneal Pharmaceuticals, was first approved by FDA on Mar 8, 2016, with 3 approved supplements and 0 published complete response letters.
Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 8, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Aspirin and Dipyridamole25MG;200MG · capsule, extended release;oral | Aspirin; Dipyridamole | Rx |
| Jul 29, 2025 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jul 29, 2025 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jul 29, 2025 | Supplement 24Labeling · Standard review | Approved | None posted |
| Mar 8, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters